By Karen Roman Agendia, Inc. said it will present data to assess treatment decisions on patients with early-stage breast cancer at the San Antonio Breast Cancer Symposium 2024. The studies will show how genomic testing can predict patients’ response to chemotherapy,...

By Karen Roman Institutional target allocations to real estate are set to decline in 2025 after holding steady at 10.8% for two years, according to the Institutional Real Estate Allocations Monitor published by Hodes Weill and Cornell University. Signs of...

By Karen Roman Agendia, Inc. said it will present MammaPrint’s ability to predict chemotherapy benefit in patients with early-stage breast cancer at the San Antonio Breast Cancer Symposium 2024. “This study highlights the ability of MammaPrint to provide a comprehensive...

By Karen Roman Candel Therapeutics, Inc. (Nasdaq: CADL) said Phase 3 of its prostate cancer candidate CAN-2409 showed an upgrade in disease-free survival in intermediate-to-high-risk patients. “We look forward to working with the FDA, as a next step, to seek...

By Karen Roman Biopharma company Lisata Therapeutics, Inc. (Nasdaq: LSTA) said it finished patient enrollment for the next stage of its CENDIFOX trial. The study will assess the safety and effects of combining certepetide, Lisata’s cyclic peptide candidate, with FOLFIRINOX-based...

By Karen Roman ReAlta Life Sciences said it is presenting new data at the American Society of Hematology (ASH) Annual Meeting in San Diego, California for its drug candidate in acute Graft-versus-Host Disease (aGVHD), pegtarazimod. The study showed significant improvement...

By Daniella Nanox (Nasdaq: NNOX), received FDA clearance to produce tomographic images for broader diagnostic applications, the company said. Nanox.ARC, now deployed in healthcare facilities across seven U.S. states, utilize proprietary tomosynthesis technology with a cold cathode, the system delivers...

By Karen Roman OmniScience and INmune Bio, Inc. (Nasdaq: INMB) said they’re using genAI in an Alzheimer’s disease trial. The AI will support the live clinical trial and is expected to increase efficiency and the probability of success, both companies...

  By Karen Roman Agendia, Inc. said its gene expression profiling test MammaPrint can predict extended endocrine therapy benefit for patients with early-stage breast cancer. The test helps optimizing additional therapy and can potentially improve survival, the company said. “These...

PE Edge and Exec Edge are pleased to provide complete video coverage of the fourth annual Palm Beach CorpGov Forum held on Nov. 13-14, featuring a two-day event with panels, firesides and networking receptions. The audience comprised more than 200 attendees...